Etzer Darout
Stock Analyst at Barclays
(4.93)
# 196
Out of 5,118 analysts
568
Total ratings
53.8%
Success rate
23.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Reiterated: Buy | $7 | $3.10 | +125.81% | 31 | Nov 6, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Buy | $53 | $29.87 | +77.44% | 10 | Nov 6, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterated: Buy | $28 | $10.54 | +165.65% | 8 | Nov 6, 2026 | |
| CTMX CytomX Therapeutics | Reiterated: Buy | $16 | $2.19 | +630.59% | 33 | Nov 6, 2026 | |
| IOVA Iovance Biotherapeutics | Reiterated: Buy | $18 → $19 | $8.04 | +136.32% | 17 | Nov 6, 2026 | |
| JANX Janux Therapeutics | Reiterated: Sell | $14 → $15 | $17.63 | -14.92% | 8 | Nov 6, 2026 | |
| LEGN Legend Biotech | Reiterated: Buy | $68 | $23.40 | +190.60% | 14 | Nov 6, 2026 | |
| ONC BeOne Medicines AG | Reiterated: Buy | $415 → $446 | $406.96 | +9.59% | 11 | Nov 6, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $180 | $132.04 | +36.32% | 14 | Nov 6, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | $78 | $49.43 | +57.80% | 3 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $18.60 | +61.29% | 8 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $12.21 | +145.70% | 14 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $35.75 | +25.87% | 35 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $6.41 | +212.01% | 37 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 | $16.33 | +22.47% | 15 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 | $47.90 | +35.70% | 9 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $271 → $275 | $234.76 | +17.14% | 10 | Nov 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $9.54 | +287.84% | 17 | Nov 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $49 → $54 | $69.57 | -22.38% | 35 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $139 → $143 | $119.65 | +19.52% | 19 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $102.86 | +55.55% | 10 | Oct 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $2.33 | +157.51% | 35 | Oct 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $148 | $85.73 | +72.64% | 13 | Oct 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $58 | $46.94 | +23.56% | 22 | Oct 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $46.45 | +61.46% | 14 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $128 → $145 | $71.42 | +103.02% | 10 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $7.27 | +285.14% | 15 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $3 | $0.9578 | +213.22% | 10 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $119 | $131.73 | -9.66% | 5 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $3.80 | n/a | 1 | Apr 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 → $143 | $87.51 | n/a | 10 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.61 | n/a | 10 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.84 | n/a | 16 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.87 | n/a | 7 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $53.63 | n/a | 11 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $15.30 | n/a | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $162.55 | n/a | 7 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.25 | n/a | 4 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $63 | $16.86 | n/a | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 → $37 | $93.72 | n/a | 2 | Sep 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $0.000001 | n/a | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $60 | $0.2219 | n/a | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 → $25 | $9.36 | n/a | 2 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $48 | $2.30 | n/a | 2 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €23.25 → €26.82 | €3.40 | n/a | 2 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $162 | $155.94 | n/a | 1 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $29.63 | n/a | 4 | Jul 14, 2020 |
C4 Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $7
Current: $3.10
Upside: +125.81%
Celldex Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $53
Current: $29.87
Upside: +77.44%
Corvus Pharmaceuticals
Nov 6, 2026
Reiterated: Buy
Price Target: $28
Current: $10.54
Upside: +165.65%
CytomX Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $16
Current: $2.19
Upside: +630.59%
Iovance Biotherapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $18 → $19
Current: $8.04
Upside: +136.32%
Janux Therapeutics
Nov 6, 2026
Reiterated: Sell
Price Target: $14 → $15
Current: $17.63
Upside: -14.92%
Legend Biotech
Nov 6, 2026
Reiterated: Buy
Price Target: $68
Current: $23.40
Upside: +190.60%
BeOne Medicines AG
Nov 6, 2026
Reiterated: Buy
Price Target: $415 → $446
Current: $406.96
Upside: +9.59%
Protagonist Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $180
Current: $132.04
Upside: +36.32%
Enliven Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $78
Current: $49.43
Upside: +57.80%
Nov 5, 2026
Reiterated: Buy
Price Target: $30
Current: $18.60
Upside: +61.29%
Nov 5, 2026
Reiterated: Buy
Price Target: $30
Current: $12.21
Upside: +145.70%
Nov 5, 2026
Reiterated: Buy
Price Target: $45
Current: $35.75
Upside: +25.87%
Nov 4, 2026
Reiterated: Buy
Price Target: $20
Current: $6.41
Upside: +212.01%
Nov 4, 2026
Reiterated: Hold
Price Target: $20
Current: $16.33
Upside: +22.47%
Nov 4, 2026
Reiterated: Buy
Price Target: $65
Current: $47.90
Upside: +35.70%
Nov 3, 2026
Reiterated: Buy
Price Target: $271 → $275
Current: $234.76
Upside: +17.14%
Nov 3, 2026
Reiterated: Buy
Price Target: $37
Current: $9.54
Upside: +287.84%
Oct 30, 2026
Reiterated: Hold
Price Target: $49 → $54
Current: $69.57
Upside: -22.38%
Oct 30, 2026
Reiterated: Buy
Price Target: $139 → $143
Current: $119.65
Upside: +19.52%
Oct 27, 2026
Reiterated: Buy
Price Target: $160
Current: $102.86
Upside: +55.55%
Oct 26, 2026
Reiterated: Buy
Price Target: $6
Current: $2.33
Upside: +157.51%
Oct 20, 2026
Reiterated: Buy
Price Target: $148
Current: $85.73
Upside: +72.64%
Oct 9, 2026
Reiterated: Hold
Price Target: $58
Current: $46.94
Upside: +23.56%
Sep 22, 2026
Reiterated: Buy
Price Target: $75
Current: $46.45
Upside: +61.46%
Sep 11, 2026
Reiterated: Buy
Price Target: $128 → $145
Current: $71.42
Upside: +103.02%
Sep 10, 2026
Reiterated: Buy
Price Target: $28
Current: $7.27
Upside: +285.14%
Aug 20, 2026
Reiterated: Sell
Price Target: $3
Current: $0.9578
Upside: +213.22%
Dec 8, 2025
Reiterated: Buy
Price Target: $70 → $119
Current: $131.73
Upside: -9.66%
Apr 4, 2025
Reiterated: Buy
Price Target: $9
Current: $3.80
Upside: n/a
Mar 11, 2025
Reiterated: Buy
Price Target: $130 → $143
Current: $87.51
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.61
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.84
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.87
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $53.63
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $15.30
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $162.55
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $9.25
Upside: n/a
Feb 27, 2025
Initiated Coverage: Buy
Price Target: $63
Current: $16.86
Upside: n/a
Sep 13, 2021
Reiterated: Buy
Price Target: $38 → $37
Current: $93.72
Upside: n/a
May 18, 2021
Initiated Coverage: Buy
Price Target: $7
Current: $0.000001
Upside: n/a
May 18, 2021
Initiated Coverage: Buy
Price Target: $60
Current: $0.2219
Upside: n/a
Mar 17, 2021
Reiterated: Buy
Price Target: $16 → $25
Current: $9.36
Upside: n/a
Mar 11, 2021
Reiterated: Buy
Price Target: $50 → $48
Current: $2.30
Upside: n/a
Mar 5, 2021
Reiterated: Buy
Price Target: €23.25 → €26.82
Current: €3.40
Upside: n/a
Feb 22, 2021
Downgraded: Hold
Price Target: $162
Current: $155.94
Upside: n/a
Jul 14, 2020
Reiterated: Buy
Price Target: $48
Current: $29.63
Upside: n/a